{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:00:25Z","timestamp":1780974025397,"version":"3.54.1"},"reference-count":17,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"abstract":"<jats:p>\n                    Prostate cancer is the most common type of cancer in men but there is no national screening programme in the UK or in most other countries. The UK National Screening Committee (UK NSC) is the independent advisory body responsible for providing evidence\u2010based recommendations to ministers in the four UK nations regarding screening programmes. Following the expansion of its remit to include targeted screening (2022) and the publication of new long\u2010term trial data, the UK NSC launched a comprehensive review of prostate cancer screening in 2025. To inform this review, a bespoke economic model was commissioned, drawing on best available evidence and input from clinicians, technical experts, and patient representatives. The model evaluated whole\u2010population screening and targeted strategies for men at higher risk. Based on the modelling study and consultation with stakeholders, the UK NSC recommended against whole\u2010population screening and screening in most targeted groups. The UK NSC has recommended screening for men with a pathogenic\n                    <jats:italic>BRCA2<\/jats:italic>\n                    variant with a family history of breast, ovarian, pancreatic, or prostate cancer. This was the only group where the UK NSC had confidence that screening would do more good than harm, primarily because prostate cancer tends to be more aggressive in this group. This narrative review describes the process taken by the UK NSC in developing its recommendations and highlights where additional evidence is still needed.\n                  <\/jats:p>","DOI":"10.1111\/bju.70355","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T02:49:28Z","timestamp":1780973368000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["More harm than good? The\n                    <scp>UK<\/scp>\n                    National Screening Committee's latest review of prostate cancer screening"],"prefix":"10.1111","author":[{"given":"Talia","family":"Boshari","sequence":"first","affiliation":[{"name":"Public Health Specialty Registrar  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Health and Social Care UK National Screening Committee  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Richards","sequence":"additional","affiliation":[{"name":"Department of Health and Social Care UK National Screening Committee  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a low\u2010intensity PSA\u2010based screening intervention on prostate cancer mortality: the CAP Randomized Clinical Trial","volume":"319","author":"Martin RM","year":"2018","journal-title":"JAMA"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16\u2010yr follow\u2010up of the European randomized study of screening for prostate cancer (figure presented.)","volume":"76","author":"Hugosson J","year":"2019","journal-title":"Eur Urol"},{"key":"e_1_2_10_4_1","unstructured":"Recommendations | Prostate cancer: diagnosis and management | Guidance | NICE."},{"key":"e_1_2_10_5_1","unstructured":"Expert\u2010derived summary statistic based on the G\u00f6teborg II Screening Study CAP Screening Trial and CAESAR studies."},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamaoncol.2024.0734","article-title":"Magnetic resonance imaging in prostate cancer screening: a systematic review and meta\u2010analysis","volume":"10","author":"Fazekas T","year":"2024","journal-title":"JAMA Oncol"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/bju.15906","article-title":"A systematic review on the outcomes of local anaesthetic transperineal prostate biopsy","volume":"131","author":"Kanagarajah A","year":"2023","journal-title":"BJU Int"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmorw.2024.100073","article-title":"Using real world data to bridge the evidence gap left by prostate cancer screening trials","volume":"1","author":"Norori N","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11701-025-03023-8","article-title":"Comparative effectiveness of robotic and laparoscopic radical prostatectomy: a GRADE\u2010assessed systematic review and meta\u2010analysis of randomized controlled trials featuring geographic subgroup analyses","volume":"20","author":"Mirza W","year":"2025","journal-title":"J Robot Surg"},{"key":"e_1_2_10_10_1","first-page":"238","article-title":"Reevaluating the definition of clinically significant prostate cancer as grade groups 2 to 5: an imperative for improved risk stratification","volume":"213","author":"Carlsson SV","year":"2025","journal-title":"J Urol"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate\u2010specific antigen screening and 15\u2010year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial","volume":"331","author":"Martin RM","year":"2024","journal-title":"JAMA"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European study of prostate cancer screening \u2010 23\u2010year follow\u2010up","volume":"393","author":"Roobol MJ","year":"2025","journal-title":"N Engl J Med"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-021-01675-5","article-title":"BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta\u2010analysis","volume":"126","author":"Nyberg T","year":"2021","journal-title":"Br J Cancer"},{"key":"e_1_2_10_14_1","unstructured":"TRANSFORM trial | Prostate Cancer UK [Internet]. [cited 2026 May 8]. Available from:https:\/\/prostatecanceruk.org\/research\/transform\u2010trial"},{"key":"e_1_2_10_15_1","unstructured":"Prostate cancer statistics | Cancer Research UK [Internet]. [cited 2026 May 11]. Available from:https:\/\/www.cancerresearchuk.org\/health\u2010professional\/cancer\u2010statistics\/statistics\u2010by\u2010cancer\u2010type\/prostate\u2010cancer"},{"key":"e_1_2_10_16_1","unstructured":"Context | Prostate cancer: diagnosis and management | Guidance | NICE [Internet]. [cited 2026 May 11]. Available from:https:\/\/www.nice.org.uk\/guidance\/ng131\/chapter\/Context"},{"key":"e_1_2_10_17_1","first-page":"601","article-title":"Racial\/ethnic disparities in patient experiences with care and Gleason score at diagnosis of prostate cancer: a SEER\u2010CAHPS study","volume":"33","author":"Navarro S","year":"2022","journal-title":"Cancer Causes Control"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1097\/JS9.0000000000000193","article-title":"Robotic\u2010assisted versus laparoscopic radical prostatectomy for prostate cancer: the first separate systematic review and meta\u2010analysis of randomised controlled trials and non\u2010randomised studies","volume":"109","author":"Ma J","year":"2023","journal-title":"Int J Surg"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70355","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.70355","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T02:49:36Z","timestamp":1780973376000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.70355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":17,"alternative-id":["10.1111\/bju.70355"],"URL":"https:\/\/doi.org\/10.1111\/bju.70355","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bju.70355"}}